0000899243-22-009061.txt : 20220303
0000899243-22-009061.hdr.sgml : 20220303
20220303161552
ACCESSION NUMBER: 0000899243-22-009061
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220303
DATE AS OF CHANGE: 20220303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAHAFFY PATRICK J
CENTRAL INDEX KEY: 0001266569
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 22708931
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-01
0
0001466301
Clovis Oncology, Inc.
CLVS
0001266569
MAHAFFY PATRICK J
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
1
1
0
0
See Remarks
Stock Option (right to buy)
1.95
2022-03-01
4
A
0
220000
0.00
A
2032-03-01
Common Stock
220000
220000
D
Stock Option (right to buy)
1.95
2022-03-01
4
A
0
80000
0.00
A
2032-03-01
Common Stock
80000
80000
D
Stock Option (right to buy)
1.95
2022-03-01
4
A
0
80000
0.00
A
2032-03-01
Common Stock
80000
80000
D
The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021.
The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024.
President and Chief Executive Officer
/s/ Patrick Mahaffy
2022-03-02